Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma

Cancer Gene Therapy volume 11, pages 408–418 (2004)Cite this article

Abstract

Suicide gene therapy of malignant melanoma essentially requires efficient gene transfer and highly selective therapeutic gene expression. To achieve this, recombinant adeno-associated virus (rAAV) particles were constructed containing the tissue-specific promoter of the human melanoma inhibitory activity (hMIA) gene combined with four copies of the enhancer element of the murine tyrosinase gene. Three melanoma and one cervix carcinoma cell line were infected with rAAV particles carrying a reporter gene under control of the enhancer/hMIA promoter in order to determine transcriptional activity and specificity of this system. Viral particles containing the enhancer/hMIA promoter mediated reporter gene activity only in melanoma cells, whereas infection with a cytomegalovirus (CMV)-based promoter construct induced unspecific gene expression. Correspondingly, transient transduction with viral particles bearing the HSVtk gene under the control of the enhancer/MIA promoter elements followed by treatment with ganciclovir (GCV) resulted in growth inhibition only in melanoma cells, whereas the CMV promoter-based construct induced unspecific cytotoxicity. In vivo experiments in nude mice demonstrated that tumors originating from human melanoma cells disappeared after stable, but not transient transduction with vectors bearing the HSVtk gene under the control of the enhancer/hMIA promoter in response to GCV application. In face of higher transduction efficiency, these rAAV particles might therefore be a useful tool for suicide gene therapy of malignant melanoma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Koh HK . Cutaneous melanoma. N Engl J Med. 1991;325:171–182.

    Article  CAS  PubMed  Google Scholar 

  2. Glass AG, Hoover RN . The emerging epidemic of melanoma and squamous cell skin cancer. JAMA. 1989;262:2097–2100.

    Article  CAS  PubMed  Google Scholar 

  3. Rigel DS, Kopf AW, Friedman RJ . The rate of malignant melanoma in the United States: are we making an impact? J Am Acad Dermatol. 1987;17:1050–1053.

    Article  CAS  PubMed  Google Scholar 

  4. Young RC . Cancer statistics, 2002: progress or cause for concern? CA Cancer J Clin. 2002;52:6–7.

    Article  PubMed  Google Scholar 

  5. McMasters KM, Sondak VK, Lotze MT, Ross MI . Recent advances in melanoma staging and therapy. Ann Surg Oncol. 1999;6:467–475.

    Article  CAS  PubMed  Google Scholar 

  6. Ezzeddine ZD, Martuza RL, Platika D, et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. N Biol. 1991;3:608–614.

    CAS  Google Scholar 

  7. Heyman RA, Borrelli E, Lesley J, et al. Thymidine kinase obliteration: creation of transgenic mice with controlled immune deficiency. Proc Natl Acad Sci USA. 1989;86:2698–2702.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Takamiya Y, Short MP, Ezzeddine ZD, Moolten FL, Breakefield XO, Martuza RL . Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J Neurosci Res. 1992;33:493–503.

    Article  CAS  PubMed  Google Scholar 

  9. Berns KI, Bohenzky RA . Adeno-associated viruses: an update. Adv Virus Res. 1987;32:243–306.

    Article  CAS  PubMed  Google Scholar 

  10. Conrad CK, Allen SS, Afione SA, et al. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Therapy. 1996;3:658–668.

    CAS  PubMed  Google Scholar 

  11. Kessler PD, Podsakoff GM, Chen X, et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA. 1996;93:14082–14087.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Fisher KJ, Jooss K, Alston J, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med. 1997;3:306–312.

    Article  CAS  PubMed  Google Scholar 

  13. Herzog RW, Hagstrom JN, Kung SH, et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA. 1997;94:5804–5809.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kaplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet. 1994;8:148–154.

    Article  CAS  PubMed  Google Scholar 

  15. Podsakoff G, Wong Jr KK, Chatterjee S . Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J Virol. 1994;68:5656–5666.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Russell DW, Miller AD, Alexander IE . Adeno-associated virus vectors preferentially transduce cells in S phase. Proc Natl Acad Sci USA. 1994;91:8915–8919.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Alexander IE, Russell DW, Spence AM, Miller AD . Effects of gamma irradiation on the transduction of dividing and nondividing cells in brain and muscle of rats by adeno-associated virus vectors. Hum Gene Ther. 1996;7:841–850.

    Article  CAS  PubMed  Google Scholar 

  18. Cheung AK, Hoggan MD, Hauswirth WW, Berns KI . Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells. J Virol. 1980;33:739–748.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Laughlin CA, Cardellichio CB, Coon HC . Latent infection of KB cells with adeno-associated virus type 2. J Virol. 1986;60:515–524.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Vile RG, Hart IR . Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res.. 1993;53:3860–3864.

    CAS  PubMed  Google Scholar 

  21. Vile R, Miller N, Chernajovsky Y, Hart I . A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Gene Therapy. 1994;1:307–316.

    CAS  PubMed  Google Scholar 

  22. Vile RG, Hart IR . In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 1993;53:962–967.

    CAS  PubMed  Google Scholar 

  23. Vile RG, Hart IR . Targeting of cytokine gene expression to malignant melanoma cells using tissue specific promoter sequences. Ann Oncol. 1994;5 (Suppl 4):59–65.

    Article  PubMed  Google Scholar 

  24. Hart IR, Vile RG . Targeted therapy for malignant melanoma. Curr Opin Oncol. 1994;6:221–225.

    Article  CAS  PubMed  Google Scholar 

  25. Hart IR, Vile RG . Targeted gene therapy. Br Med Bull. 1995;51:647–655.

    Article  CAS  PubMed  Google Scholar 

  26. Stoll R, Renner C, Zweckstetter M, et al. The extracellular human melanoma inhibitory activity (MIA) protein adopts an SH3 domain-like fold. EMBO J. 2001;20:340–349.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Bosserhoff AK, Echtenacher B, Hein R, Buettner R . Functional role of melanoma inhibitory activity in regulating invasion and metastasis of malignant melanoma cells in vivo. Melanoma Res. 2001;11:417–421.

    Article  CAS  PubMed  Google Scholar 

  28. Bosserhoff AK, Kaufmann M, Kaluza B, et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res. 1997;57:3149–3153.

    CAS  PubMed  Google Scholar 

  29. Stahlecker J, Gauger A, Bosserhoff A, Buttner R, Ring J, Hein R . MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Anticancer Res. 2000;20:5041–5044.

    CAS  PubMed  Google Scholar 

  30. Bosserhoff AK, Hein R, Bogdahn U, Buettner R . Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA. J Biol Chem. 1996;271:490–495.

    Article  CAS  PubMed  Google Scholar 

  31. Bosserhoff AK, Kondo S, Moser M, et al. Mouse CD-RAP/MIA gene: structure, chromosomal localization, and expression in cartilage and chondrosarcoma. Dev Dyn. 1997;208:516–525.

    Article  CAS  PubMed  Google Scholar 

  32. Bosserhoff AK, Moser M, Hein R, Landthaler M, Buettner R . In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers. J Pathol. 1999;187:446–454.

    Article  CAS  PubMed  Google Scholar 

  33. Zolotukhin S, Potter M, Hauswirth WW, Guy J, Muzyczka N . A “humanized” green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol. 1996;70:4646–4654.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Rothfels H, Paschen A, Schadendorf D . Evaluation of combined gene regulatory elements for transcriptional targeting of suicide gene expression to malignant melanoma. Exp Dermatol. 2003;12:799–810.

    Article  CAS  PubMed  Google Scholar 

  35. Ganss R, Montoliu L, Monaghan AP, Schutz G . A cell-specific enhancer far upstream of the mouse tyrosinase gene confers high level and copy number-related expression in transgenic mice. EMBO J. 1994;13:3083–3093.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Grimm D, Kern A, Rittner K, Kleinschmidt JA . Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther. 1998;9:2745–2760.

    Article  CAS  PubMed  Google Scholar 

  37. Haberkorn U, Khazaie K, Morr I, Altmann A, Muller M, van Kaick G . Ganciclovir uptake in human mammary carcinoma cells expressing herpes simplex virus thymidine kinase. Nucl Med Biol. 1998;25:367–373.

    Article  CAS  PubMed  Google Scholar 

  38. Huber BE, Richards CA, Krenitsky TA . Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA. 1991;88:8039–8043.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Harris JD, Gutierrez AA, Hurst HC, Sikora K, Lemoine NR . Gene therapy for cancer using tumour-specific prodrug activation. Gene Therapy. 1994;1:170–175.

    CAS  PubMed  Google Scholar 

  40. Smith MJ, Rousculp MD, Goldsmith KT, Curiel DT, Garver Jr RI . Surfactant protein A-directed toxin gene kills lung cancer cells in vitro. Hum Gene Ther. 1994;5:29–35.

    Article  CAS  PubMed  Google Scholar 

  41. Jiang S, Altmann A, Grimm D, et al. Tissue-specific gene expression in medullary thyroid carcinoma cells employing calcitonin regulatory elements and AAV vectors. Cancer Gene Ther. 2001;8:469–472.

    Article  CAS  PubMed  Google Scholar 

  42. Pang S, Taneja S, Dardashti K, et al. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum Gene Ther. 1995;6:1417–1426.

    Article  CAS  PubMed  Google Scholar 

  43. Miyao Y, Shimizu K, Moriuchi S, et al. Selective expression of foreign genes in glioma cells: use of the mouse myelin basic protein gene promoter to direct toxic gene expression. J Neurosci Res. 1993;36:472–479.

    Article  CAS  PubMed  Google Scholar 

  44. Ko SC, Cheon J, Kao C, et al. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res. 1996;56:4614–4619.

    CAS  PubMed  Google Scholar 

  45. Dietz UH, Sandell LJ . Cloning of a retinoic acid-sensitive mRNA expressed in cartilage and during chondrogenesis. J Biol Chem. 1996;271:3311–3316.

    Article  CAS  PubMed  Google Scholar 

  46. Hearing VJ, Tsukamoto K . Enzymatic control of pigmentation in mammals. FASEB J. 1991;5:2902–2909.

    Article  CAS  PubMed  Google Scholar 

  47. Deichmann M, Benner A, Bock M, et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol. 1999;17:1891–1896.

    Article  CAS  PubMed  Google Scholar 

  48. Ido A, Uto H, Moriuchi A, et al. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. Cancer Res. 2001;61:3016–3021.

    CAS  PubMed  Google Scholar 

  49. Modlich U, Pugh CW, Bicknell R . Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Therapy. 2000;7:896–902.

    Article  CAS  PubMed  Google Scholar 

  50. Engelmann C, Panis Y, Bolard J, et al. Liposomal encapsulation of ganciclovir enhances the efficacy of herpes simplex virus type 1 thymidine kinase suicide gene therapy against hepatic tumors in rats. Hum Gene Ther. 1999;10:1545–1551.

    Article  CAS  PubMed  Google Scholar 

  51. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann JL, Klatzmann D . Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA. 1993;90:7024–7028.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Haberkorn U, Bellemann ME, Gerlach L, et al. Uncoupling of 2-fluoro-2-deoxyglucose transport and phosphorylation in rat hepatoma during gene therapy with HSV thymidine kinase. Gene Therapy. 1998;5:880–887.

    Article  CAS  PubMed  Google Scholar 

  53. Klatzmann D, Cherin P, Bensimon G, et al. A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase “suicide” gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma. Hum Gene Ther. 1998;9:2585–2594.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany

    Frank Schoensiegel, Helmut Eskerski, Walter Mier & Uwe Haberkorn

  2. Clinical Cooperation Unit Dermato-Oncology, German Cancer Research Center, Heidelberg, Germany

    Annette Paschen & Dirk Schadendorf

  3. University Clinics Mannheim, Mannheim, Germany

    Annette Paschen & Dirk Schadendorf

  4. Schering AG, Berlin, Germany

    Stephanie Sieger

  5. ALTANA Pharma AG, Konstanz, Germany

    Heike Rothfels

  6. Department of Applied Tumor Virology, German Cancer Research Center, Heidelberg, Germany

    Juergen Kleinschmidt

Authors
  1. Frank Schoensiegel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annette Paschen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephanie Sieger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Helmut Eskerski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Walter Mier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Heike Rothfels
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Juergen Kleinschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dirk Schadendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Uwe Haberkorn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank Schoensiegel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schoensiegel, F., Paschen, A., Sieger, S. et al. MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma. Cancer Gene Ther 11, 408–418 (2004). https://doi.org/10.1038/sj.cgt.7700721

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700721

Keywords

This article is cited by

Search

Advanced search

Quick links